An open label multicenter Phase Ib/II trial to determine the dose of BI 836826 in combination with gemcitabine and oxaliplatin (GemOx) and the efficacy of BI 836826 – GemOx versus rituximab ( R ) with GemOx (R- GemOx) in patients with relapsed/refractory diffuse B-cell lymphoma (DLBCL) who are not eligible for, or have relapsed/progressed after autologous/allogenic stem cell transplant

SCS Boehringer Ingelheim Comm. V0 个研究点目标入组 160 人开始时间: 2015年9月18日最近更新: 2018年6月18日

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方
入组人数: 160

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•1. Age 18 years or older
•2. Patients with histologically confirmed, relapsed/refractory, diffuse large B-cell lymphoma (including transformed follicular lymphoma)
•o who have received an anti-CD20-supplemented, anthracycline-containing chemotherapy
•o are not eligible for high dose therapy followed by an autologous stem cell transplant, or have relapsed/progressed after autologous/ allogeneic stem cell transplant
•allogenic stem cell transplant performed at least 6 months prior to study entry is allowed if patients do not require immunosuppressive treatment and have no evidence of active graft-versus-host disease.
•3. Patient has not received anti-lymphoma treatment prior to the first dose of trial medication:
•o within past 14 days
•o within time that is shorter or equal to 5 half-lives of the drug if the last anti-lymphoma treatment contained an investigational agent
•4. Screening computer tomography (CT) scan with involvement of at least 1 bi-dimensional lesion/node >1.5cm
•5. Screening [18F] flourodeoxyglucose (FDG)- positron emission tomography (PET) scans must demonstrate positive lesion compatible with computer tomography (CT) defined anatomical tumor sites.
•6. ECOG performance status 0, 1, 2
•7. Written signed informed consent consistent with ICH GCP and local legislation
•8. Patients must have an acceptable organ function
•9. Women of childbearing potential* must be ready and able to use highly effective methods of birth control per ICH M3(R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. Non-vasectomized Male patients having a female sexual partner of childbearing potential must ensure their partner is using a highly effective method of birth control as described above, during the trial and for at least 12 months after the end of the trial.
•Are the trial subjects under 18? no
•Number of subjects for this age range: 0
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 32
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 128

排除标准

•? Eligible for curative salvage high dose therapy followed by stem cell transplant
•? Primary central nervous system lymphoma or known Central nervous system (CNS) involvement
•? Prior history of malignancy other than DLBCL except basal cell or squamous cell carcinoma of the skin, or carcinoma in situ of the uterine cervix or breast which has been treated with curative therapy. Other prior malignancies are allowed only if patient has been free of disease and without treatment other than hormones for at least past three years.
•? Refractory to gemcitabine and/or oxaliplatin
•? Contraindications for gemcitabine, oxaliplatin and/or rituximab as judged by the investigator. Hypersensitivity to oxaliplatin.
•? Unresolved toxicity of CTCAE grade > 1from prior anti-lymphoma therapy (except alopecia)
•? Significant concurrent medical disease or condition which according to the investigators judgment would either compromise patient safety or interfere with the evaluation of the safety of the test drug. e.g. symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia requiring therapy with the exception of extra systoles of minor conduction abnormalities
•? An infection requiring treatment at the start of the trial medication.
•? Active Hepatitis B or hepatitis C, or laboratory evidence for a chronic infection or HIV infection (test results done in routine diagnostics are acceptable if done within 14 days before the first study treatment dose)
•? Women who are pregnant, nursing, or who plan to become pregnant while in the trial. This includes the female sexual partners of a male participant.
•? Known alcohol or drug abuse which could potentially interfere with trial participation according to investigator's judgment
•? Prior treatment with CD37 antibody

研究者

发起方

SCS Boehringer Ingelheim Comm. V

相似试验

进行中（未招募）

1 期

To determine the dose of BI 836826-GemOx and the efficacy of BI 836826-GemOx versus R-GemOx in patients with relapsed/refractory DLBCPatients with relapsed/refractory DLBCL (including transformedfolicullar lymphoma) who have been pretreated with an anti-CD20monoclonal antibody (e.g. rituximab) in combination with ananthracycline containing chemotherapy and who are not eligible for, orhave failed autologous stem cell transplant.MedDRA version: 21.0Level: PTClassification code 10012822Term: Diffuse large B-cell lymphoma refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2014-004794-16-ITBOEHRINGER-INGELHEIM ITALIA S.P.A.35

进行中（未招募）

1 期

EUCTR2017-002056-86-DEAIO-Studien-gGmbH75

进行中（未招募）

1 期

Sym004 in Combitation with FOLFIRI (chemotherapy regimen) in metastatic colorectal cancerPatients with locally advanced or metastatic CRC, wild type KRAS/NRAS (exon 2, 3, 4) will be enrolled.MedDRA version: 18.1Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 100000004864

EUCTR2015-003047-19-ESSymphogen A/S50

进行中（未招募）

1 期

An experimental study in women with cervical cancer to test the safety and activation of the patient's own immune system after treatment with chemotherapy in combination with a vaccine directed against an infection with Human Papilloma Virus Type 16 (HPV16).Patients with advanced (Stage IIIb-IVa with involvement of lymph nodes beyond the renal vein) or metastatic (stage IVb )or recurrent HPV16 positive cervical cancer for whom no curative treatment options existMedDRA version: 19.0 Level: LLT Classification code 10008229 Term: Cervical cancer System Organ Class: 100000004864

EUCTR2013-001804-12-BEISA Therapeutics B.V.90

已完成

不适用

A multicenter, open label Phase I/II study to determine the safety and immune modulating effects of the therapeutic Human Papilloma Virus Type 16 (HPV16) E6/E7 Synthetic Long Peptides Vaccine (ISA101/ISA101b) immunotherapy in combination with standard of care therapy (carboplatin and paclitaxel with or without bevacizumab) in women with HPV16 positive advanced or recurrent cervical cancer who have no curative treatment options.cervical canceradvanced or recurrent cervical cancer10038594

NL-OMON45132ISA Therapeutics B.V.50